All In Biotech

Drug Trial Radar · NCT07395687

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 333 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

333

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Jan 14, 2027

Study completion Feb 18, 2027

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Feb 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.

Conditions

  • Overweight
  • Obesity

Interventions

  • UBT251Drug

    UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.

  • PlaceboDrug

    Placebo matched to UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A - Number of treatment emergent adverse events (TEAEs)Time frame: From baseline (week 0) to end of study (week 33)
  2. Part B - Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 28)
  3. Part C- AUC; the area under the UBT251 plasma concentration time curveTime frame: From pre-dose on Day 1 until completion of the end of study visit (Day 43)

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Altasciences Clinical LA, Inc.

    Cypress, California · Recruiting

  • Altasciences Clinical Kansas, Inc.

    Overland Park, Kansas · Recruiting

  • Altasciences Clinical Company, Inc

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.